Table 6.
Comparison between patients with NASH and without NASH according to anthropometric, clinical and laboratory features n (%)
|
All NAFLD patients |
P | ||
| Patients with NASH (n = 23) | Patients without NASH (n = 11) | ||
| Age (yr) | 51.17 ± 5.11 | 48.82 ± 9.05 | > 0.05 |
| Gender: male/female | 7/16 (30.4/69.6) | 4/7 (36.4/63.6) | > 0.05 |
| Hepatomegaly | 7 (29.2) | 4 (36.4) | > 0.05 |
| Obesity (BMI ≥ 30) | 23 (100) | 8 (72.7) | < 0.05 |
| Waist/hip ratio | 17 (63.6) | 7 (73.9) | > 0.05 |
| Systolic blood pressure (mmHg)1 | 120 (110-180) | 130 (110-180) | > 0.05 |
| Diastolic blood pressure (mmHg)1 | 70 (65-110) | 70 (60-120) | > 0.05 |
| Hypertension | 10 (45.5) | 6 (60) | > 0.05 |
| HDL-Cholesterol (mg/dL) | 44.09 ± 5.77 | 46.91 ± 9.66 | > 0.05 |
| Low-HDL level | 13 (56.5) | 4 (36.4) | > 0.05 |
| Triglycerides (mg/dL) | 146.61 ± 74.43 | 174.18 ± 83.85 | > 0.05 |
| Hypertriglyceridemia | 10 (43.5) | 5 (45.5) | > 0.05 |
| Fasting glucose (mg/dL)1 | 102.33 (73-195) | 100 (83-125) | > 0.05 |
| Diabetes | 6 (26.1) | 2 (18.2) | > 0.05 |
| Impaired glucose tolerance | 9 (39.1) | 1 (9.1) | > 0.05 |
| Fasting insulin (μU/mL)1 | 13.44 (4.76-47.3) | 16.60 (6-21.80) | > 0.05 |
| Insulin resistance-HOMA-IR | 13 (81.3) | 6 (66.7) | > 0.05 |
| AST (U/L)1 | 40 (14-92) | 51 (14-78) | > 0.05 |
| ALT (U/L)1 | 67 (15-158) | 82 (13-166) | > 0.05 |
| GGT (U/L)1 | 33 (15-119) | 43 (15-426) | > 0.05 |
| ALP (U/L)1 | 81 (52-152) | 81 (51-154) | > 0.05 |
| AST/ALT > 1 | 4 (17.3) | 2 (18.1) | > 0.05 |
| Metabolic syndrome | 18 (78.3) | 9 (81.8) | > 0.05 |
1
Data expressed as median (minimum-maximum); BMI: Body mass index; HOMA: Homeostasis model assessment; HDL: High-density lipoprotein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma glutamyl transpeptidase. There was a significant difference between patients with or without NASH according to the presence of obesity only.